Fig. 7
Combined overexpression of KSR2 and 14–3-3ζ is associated with poor prognosis and decreased HCC sensitivity to sorafenib. A Expression of KSR2 and 14–3-3ζ together in a TMA of cancer tissues and normal adjacent tissues, and H and E staining. B Relationship between the expression level of KSR2 and the expression level of 14–3-3ζ in a TMA. C Relationship between overall survival and expression of KSR2 and 14–3-3ζ assessed analyzed by Kaplan–Meier analysis. D Relationship between disease-free survival and expression of KSR2 and 14–3-3ζ assessed by Kaplan–Meier analysis. E, F Percentage of surviving PLC/PRF/5 cells and MHCC97H cells overexpressing KSR2 in the presence of sorafenib. n = 3 independent experiments. G Apoptosis in KSR2-overexpressing cells with 14–3-3ζ-knockdown after sorafenib treatment. H Percentage of apoptotic PLC/PRF/5 cells overexpressing KSR2 in the presence of sorafenib. n = 3 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001